Literature DB >> 2509395

Diabetic-like retinopathy in rats prevented with an aldose reductase inhibitor.

W G Robison1, M Nagata, N Laver, T C Hohman, J H Kinoshita.   

Abstract

The earliest histopathologic signs of diabetic retinopathy include selective loss of intramural pericytes and thickening of capillary basement membranes. Previous evidence from animal models indicated that aldose reductase inhibitors could prevent these capillary wall lesions, but only recently have aldose reductase inhibitors been tested for prevention of the subsequent retinal complications of diabetes, such as microaneurysms. In the present study, Sprague-Dawley rats were fed diets containing 50% galactose with or without an aldose reductase inhibitor (tolrestat). After 28 months of galactose feeding, the retinal capillaries in whole mounts exhibited a marked increase in periodic acid-Schiff (PAS) staining, extensive pericyte loss, endothelial cell proliferation, acellularity, diffuse dilation, occluded lumens, microaneurysms, and complex microvascular abnormalities including gross dilation and formation of multiple shunt networks. The PAS hyperchromaticity of basement membrane material and pericyte loss occurred throughout the retinal vasculature, while while the microaneurysms and complex lesions were limited to the capillaries of the central and paracentral retina. The changes were associated with both the arterial and venous portions of the capillary plexus. Treatment with orally administered tolrestat prevented essentially all of the vessel abnormalities. Thus, long-term galactose feeding of rats induced microvascular lesions simulating those occurring in background diabetic retinopathy in humans, and these lesions were prevented by treatment with an aldose reductase inhibitor.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2509395

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  23 in total

Review 1.  Pathogenesis of diabetic nephropathy.

Authors:  Claudia van Dijk; Tomas Berl
Journal:  Rev Endocr Metab Disord       Date:  2004-08       Impact factor: 6.514

Review 2.  The role of genetics in susceptibility to diabetic retinopathy.

Authors:  Gerald Liew; Ronald Klein; Tien Y Wong
Journal:  Int Ophthalmol Clin       Date:  2009

3.  Retinal microvascular patency in the diabetic rat.

Authors:  Joshua Ben-nun; Valerie A Alder; Ian J Constable
Journal:  Int Ophthalmol       Date:  2005-09-29       Impact factor: 2.031

4.  Cultured retinal capillary pericytes die by apoptosis after an abrupt fluctuation from high to low glucose levels: a comparative study with retinal capillary endothelial cells.

Authors:  W Li; X Liu; M Yanoff; S Cohen; X Ye
Journal:  Diabetologia       Date:  1996-05       Impact factor: 10.122

5.  Genetic and epigenetic modifications in the pathogenesis of diabetic retinopathy: a molecular link to regulate gene expression.

Authors:  Priya Pradhan; Nisha Upadhyay; Archana Tiwari; Lalit P Singh
Journal:  New Front Ophthalmol       Date:  2016-10-24

Review 6.  The versatility of microvascular pericytes: from mesenchyme to smooth muscle?

Authors:  V Nehls; D Drenckhahn
Journal:  Histochemistry       Date:  1993-01

7.  Pathophysiological characteristics of diabetic ocular complications in spontaneously diabetic torii rat.

Authors:  Tomohiko Sasase
Journal:  J Ophthalmol       Date:  2010-05-25       Impact factor: 1.909

8.  Intervention with the aldose reductase inhibitor, tolrestat, in renal and retinal lesions of streptozotocin-diabetic rats.

Authors:  M L McCaleb; M L McKean; T C Hohman; N Laver; W G Robison
Journal:  Diabetologia       Date:  1991-10       Impact factor: 10.122

9.  Electron microscopic immunocytochemical demonstration of blood-retinal barrier breakdown in human diabetics and its association with aldose reductase in retinal vascular endothelium and retinal pigment epithelium.

Authors:  S A Vinores; E Van Niel; J L Swerdloff; P A Campochiaro
Journal:  Histochem J       Date:  1993-09

10.  The effects of an aldose reductase inhibitor on the progression of diabetic retinopathy.

Authors:  A Tromp; J M Hooymans; B C Barendsen; J J van Doormaal
Journal:  Doc Ophthalmol       Date:  1991       Impact factor: 2.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.